Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 20;16(9):2591–2604. doi: 10.1158/1078-0432.CCR-09-2443

Fig 4.

Fig 4

Doxorubicin and TRAIL combination inhibits fibrosarcoma (HT1080) lung metastases growth and enhances survival. A) BLI images of one representative mice of each treatment arm are shown demonstrating the markedly decreased luciferase readout in combination treated mice compared to control or either compound alone. Pictures and H+E staining demonstrate the reduction in lung metastatic deposits (arrows) in combination treated mice; B) Box plots demonstrating the significant decrease in lung weight of combination treated mice (*p<0.005); C) Kaplan Meier survival curves demonstrating a statistically significant prolongation in overall survival of mice treated with doxorubicin/TRAIL combination (p=0.001)